Bo Albinsson

Bo Albinsson

Auto-generated profile, based on publicly available information

Bo Albinsson

Laboratory of Clinical Microbiology, Uppsala University Hospital, Uppsala, Sweden

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2001 in Journal of Clinical Microbiology
Verified
Journal Article
Open access
PDF file
AAAnnika Allard
Annika Allard
BABo Albinsson
Bo Albinsson
GWGörAn Wadell
GörAn Wadell
We have developed a system for rapid typing of adenoviruses (Ads) based on a combination of PCR and restriction endonuclease (RE) digestion (PCR-RE digestion). Degenerated consensus primers were designed, allowing amplification of DNA from all 51 human Ad prototype strains and altogether 44 different genome variants of Ad serotypes 1, 3, 4, 5, 7, 11, 19, 40, and 41. The 301-bp amplimer of 22 prototype strains representing all six subgenera and the genome variant was selected as a target for sequencing to look for subgenus and genome type variabilities. The sequences obtained were used to facilitate the selection of specific REs for discrimination purposes in a diagnostic assay by following the concept of cleavage or noncleavage of the 301-bp amplimer. On the basis of these results, a flowchart was constructed, allowing identification of subgenus B:2 and D serotypes and almost complete distinction of subgenus A, B:1, C, E, and F serotypes. Application of the PCR-RE digestion system to clinical samples allowed typing of 34 of 40 clinical samples positive for Ad. The genome type determined by this method was identical to that obtained by traditional RE typing of full-length Ad DNA. The remaining six samples were positive only after a nested PCR. Therefore, to reduce the risk of false-negative results, samples scored negative by the PCR-RE digestion system should be evaluated by the described nested PCR. Used in combination, the PCR-RE digestion method and the nested PCR provide a reliable and sensitive system that can easily be applied to all kinds of clinical samples when rapid identification of adenoviruses is needed.

1 June 1992 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
AAAnnika Allard
Annika Allard
BABo Albinsson
Bo Albinsson
GWGöran Wadell
Göran Wadell

1 November 1999 in Virus Research
Verified
Journal Article
Closed access
BABo Albinsson
Bo Albinsson
AKAlistair H Kidd
Alistair H Kidd

18 January 2018 in Eurosurveillance
Verified
Journal Article
Open access
BABo Albinsson
Bo Albinsson
SVSirkka Vene
Sirkka Vene
LRLars Rombo
Lars Rombo
JBJonas Blomberg
Jonas Blomberg
ÅLÅke Lundkvist
Åke Lundkvist
BRBengt Ronnberg
Bengt Ronnberg
Tick-borne encephalitis virus (TBEV) is an important European vaccine-preventable pathogen. Discrimination of vaccine-induced antibodies from those elicited by infection is important. We studied anti-TBEV IgM/IgG responses, including avidity and neutralisation, by multiplex serology in 50 TBEV patients and 50 TBEV vaccinees. Infection induced antibodies reactive to both whole virus (WV) and non-structural protein 1 (NS1) in 48 clinical cases, whereas 47 TBEV vaccinees had WV, but not NS1 antibodies, enabling efficient discrimination of infection/vaccination.

11 January 2024 in Eurosurveillance
Verified
Journal Article
Open access
BABo Albinsson
Bo Albinsson
THTove Hoffman
Tove Hoffman
LKLinda Kolstad
Linda Kolstad
ABand Tomas Bergström
and Tomas Bergström
GBGordana Bogdanovic
Gordana Bogdanovic
ÅLÅke Lundkvist
Åke Lundkvist
Background: In Sweden, information on seroprevalence of tick-borne encephalitis virus (TBEV) in the population, including vaccination coverage and infection, is scattered. This is largely due to the absence of a national tick-borne encephalitis (TBE) vaccination registry, scarcity of previous serological studies and use of serological methods not distinguishing between antibodies induced by vaccination and infection. Furthermore, the number of notified TBE cases in Sweden has continued to increase in recent years despite increased vaccination. Aim: The aim was to estimate the TBEV seroprevalence in Sweden. Methods: In 2018 and 2019, 2,700 serum samples from blood donors in nine Swedish regions were analysed using a serological method that can distinguish antibodies induced by vaccination from antibodies elicited by infection. The regions were chosen to reflect differences in notified TBE incidence. Results: The overall seroprevalence varied from 9.7% (95% confidence interval (CI): 6.6–13.6%) to 64.0% (95% CI: 58.3–69.4%) between regions. The proportion of vaccinated individuals ranged from 8.7% (95% CI: 5.8–12.6) to 57.0% (95% CI: 51.2–62.6) and of infected from 1.0% (95% CI: 0.2–3.0) to 7.0% (95% CI: 4.5–10.7). Thus, more than 160,000 and 1,600,000 individuals could have been infected by TBEV and vaccinated against TBE, respectively. The mean manifestation index was 3.1%. Conclusion: A difference was observed between low- and high-incidence TBE regions, on the overall TBEV seroprevalence and when separated into vaccinated and infected individuals. The estimated incidence and manifestation index argue that a large proportion of TBEV infections are not diagnosed.

20 July 2020 in Upsala Journal of Medical Sciences
Verified
Journal Article
Open access
ALAnna-Karin Lidström
Anna-Karin Lidström
FSFredrik Sund
Fredrik Sund
BABo Albinsson
Bo Albinsson
JLJohan Lindbäck
Johan Lindbäck
GWGabriel Westman
Gabriel Westman
During the Covid-19 pandemic, the protection of healthcare workers has been in focus throughout the world, but the availability and quality of personal protective equipment has at times and in some...